An experimental treatment for TK2 deficiency based on deoxynucleoside supplementation has been developed and tested in mouse models expressing pathogenic TK2 variants (Akman et al., 2008; Garone et al., 2014), as well as in patients. Here, TK2 is linked to hyperinsulinemic hypoglycemia, familial, 4.